Switzerland-based Idorsia Pharmaceuticals Ltd (SWX: IDIA) confirmed the closing of a senior secured term loan facility of up to CHF 250 million (approximately USD 278 million) with investment funds managed by Pharmakon Advisors, LP, using the first tranche to retire near-term debt and extend its cash runway as its commercial-stage insomnia franchise continues to scale. The transaction directly addresses a May 2027 debt maturity that had weighed on the company's balance sheet, replacing a shorter-dated facility with five-year non-dilutive debt.
At closing, Idorsia drew the first tranche of CHF 150 million (approximately USD 167 million) and applied a portion to fully repay the CHF 105 million drawn under its existing New Money Facility, including original issue discount and accrued interest. The new Pharmakon facility carries a fixed 7% interest rate and a five-year maturity, with additional tranches available. Pharmakon Advisors, acting as investment manager of the BioPharma Credit funds, has committed up to USD 13 billion across 77 life sciences investments since 2009. The transaction is purely debt-based, with no equity or dilutive components. Pharmakon has recently provided debt financing to other biopharma companies including Mineralys Therapeutics and UroGen Pharma, underscoring its position as a repeat lender in the sector.
Idorsia is focused on developing and commercializing small-molecule drugs. Its lead commercial asset is daridorexant (QUVIVIQ), a dual orexin receptor antagonist approved for insomnia in major markets. The company reported CHF 134 million in QUVIVIQ net sales for full-year 2025. Management has stated that the Pharmakon facility extends the cash runway well into 2028, providing financial flexibility to execute commercial and pipeline objectives without near-term refinancing pressure.